Diseases of urachal remnants are uncommon and generally located on the junction of the urachal remnant with the bladder dome. In most cases such diseases correspond to mucinous adenocarcinomas and present hematuria as their most common clinical finding. The authors report the case of a 62-year-old female patient undergoing follow-up due to macroscopic hematuria for three years. Ultrasonography and computed tomography findings are described.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341378 | PMC |
| http://dx.doi.org/10.1590/0100-3984.2013.1879 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[SUCCESSFUL TREATMENT WITH mFOLFOX6 FOR URACHAL ADENOCARCINOMA WITH MULTIPLE LUNG METASTASIS: A CASE REPORT].
Nihon Hinyokika Gakkai Zasshi
January 2025
Department of Urology, Yokohama Municipal Citizen's Hospital.
We report the case of a 41-year-old man who presented with gross hematuria and a bladder tumor on ultrasonography. Magnetic resonance imaging indicated a possible muscle-invasive bladder cancer or urachal carcinoma. Following transurethral resection of the bladder tumor, histopathological findings revealed an adenocarcinoma similar to colorectal cancer.
View Article and Find Full Text PDFPrecision Oncology Approach for Urachal Carcinoma: A Clinical Case Report.
Int J Mol Sci
December 2024
Department of Urology, Semmelweis University, Üllői Street 78/b, H-1082 Budapest, Hungary.
Urachal cancer (UrC) is a rare disease which is mostly diagnosed late due to symptoms caused by its local invasion to the urinary bladder. Given the lack of clinical trials and guideline recommendations for systemic treatment, a molecularly informed precision oncology approach is a viable option for UrC already in the early lines of systemic treatment. While single case experiences may provide valuable reference for later decision-making, well-documented clinical experience with off-label targeted treatments is limited to a few patients.
View Article and Find Full Text PDFSurgical treatment of urachal adenocarcinoma with lung metastasis: A case report and literature review.
Thorac Cancer
December 2024
Department of Thoracic Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Article Synopsis
- * Most urachal cancers are classified as intestinal adenocarcinomas (90%), and they often occur in the lower urachal tube or bladder dome, leading to late diagnoses due to the silent nature of early stages.
- * Treatment options for this aggressive cancer include surgery and chemotherapy (like cisplatin), with some patients showing positive responses to targeted therapies; a case study highlighted successful surgical treatment for a patient with advanced disease.
Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status.
Cancer Med
October 2024
Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.
Background And Aim: Pseudomyxoma peritonei (PMP) is an unusual condition with unique behaviour caused by a mucinous neoplasm, usually arising from the appendix. The aim of this study was to evaluate the prevalence of genomic alterations in clinical specimens of PMP using a targeted assay and correlate the findings with clinical, pathological and outcome data. Sequencing data from 223 patients were analysed.
View Article and Find Full Text PDFUrachal carcinoma initially presenting only as a liver metastasis, a diagnostic and therapeutic challenge: first case in literature.
Ann Med Surg (Lond)
October 2024
Cancer Research Center, Tishreen University Hospital.
Introduction: Urachal carcinomas are uncommon malignant neoplasms comprising only 0.01% of all adult cancers. Most patients were aged from 58 to 64 years at diagnosis with 60 years being the median.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!